Pfizer, Inc. (PFE) News

Pfizer, Inc. (PFE)

Today's Latest Price: $38.18 USD

0.75 (2.00%)

Updated Oct 23 7:00pm

Add PFE to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter PFE News Items

PFE News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest PFE News From Around the Web

Below are the latest news stories about Pfizer Inc that investors may wish to consider to help them evaluate PFE as an investment opportunity.

Sertraline Hydrochloride Tablet Market to Record Significant Revenue Growth during the Forecast Period 2020–2025 | PIDI, Cy Pharm, Pfizer, Accord-Healthcare, Exelan, Greenstone, Cipla, Lupins

This report provides in-depth study on the current state of the Global Sertraline Hydrochloride Tablet Market 2020-2025. Key players in the Global Sertraline Hydrochloride Tablet Market have been identified through the secondary research and their market share has been determined

OpenPR | October 2, 2020

Insulin Market is Forecast To Reach USD 35.74 Billion By 2027 | Sanofi, Eli Lily and Company, ADOCIA, Julphar, Pfizer, Inc

The latest updated report on the Global Insulin Market added by Reports and Data presents a comprehensive analysis of the industry size, revenue forecast, regional spectrum of the business vertical, and further elaborates on the major hurdles, challenges, and latest

OpenPR | October 2, 2020

Fibromyalgia Drugs Market Capacity, Production, Revenue, Price and Gross Margin, Industry Analysis & Forecast by 2026| Pfizer, Eli Lilly, Actavis

Fibromyalgia Drugs Market is expected to grow significantly over next few years and generate considerable market for Fibromyalgia Drugs. Market Report Expert has recently published a research report titled, “ Fibromyalgia Drugs Market Outlook and Statistics, 2020-2026". The report has been

OpenPR | October 2, 2020

Trump at high risk of serious Covid-19 illness - STAT

Pfizer CEO Albert Bourla told employees he was disappointed that its work developing a Covid-19 vaccine has been politicized.

STAT News | October 2, 2020

Report: Pfizer CEO tell employees COVID-19 vaccine will move only at 'speed of science'

Shares of Pfizer Inc. undefined were down 0.1% in premarket trading on Friday, the day after the Associated Press reported that CEO Albert Bourla had…

MarketWatch | October 2, 2020

Moderna, Pfizer & BioNTech, and AstraZeneca and the University of Oxford's COVID-19 Vaccine Trials are Entering the Final Stage of Development

DUBLIN, Oct. 2, 2020 /PRNewswire/ -- ResearchAndMarkets.com published a new article on the vaccine industry "COVID-19 Vaccine Trials are Entering the Final Stage of Development" Johnson & Johnson has begun final stage testing of its COVID-19 vaccine candidate. The company will trial the…

PR Newswire | October 2, 2020

Global Gene Delivery Systems Market Research Report 2020 Featuring Amgen, Bayer, Human Stem Cells Institute, J&J, Novartis, Oxford, Biomedica, Pfizer, Shanghai Sunway Biotech, Sibiono GeneTech - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Gene Delivery Systems - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Gene Delivery Systems Market to Reach $4 Billion by 2027 Amid the COVID-19 crisis, the global market for Gene Delivery Systems estimated at US$2.6 Billion in the year 2020, is projected to reach a revised size of US$4 Billion by 2027, growing at a CAGR of 6.4% over the period 2020-2027. Viral Gene Delivery, one of the segments analyze

Business Wire | October 2, 2020

Global Pneumonia Therapeutics Market Trajectory & Analytics Report 2020 Featuring Abbott Labs, Allergan, Bayer, GlaxoSmithKline, Lupin Pharma, Merck & Co, Novartis & Pfizer - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Pneumonia Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Pneumonia Therapeutics Market to Reach US$22.5 Billion by the Year 2027 Amid the COVID-19 crisis, the global market for Pneumonia Therapeutics estimated at US$14.5 Billion in the year 2020, is projected to reach a revised size of US$22.5 Billion by 2027, growing at a CAGR of 6.5% over the analysis period 2020-2027. Drugs, one of the

Business Wire | October 2, 2020

Pfizer CEO says ‘political pressure’ won’t affect COVID-19 vaccine efforts

Pfizer CEO Albert Bourla said politics won’t influence his company’s push to produce a coronavirus vaccine after President Trump claimed a shot could be ready in weeks. In an open letter to Pfizer employees, Bourla said the New York-based drugmaker is moving at “the speed of science” to develop a vaccine but expressed concern that…

New York Post | October 2, 2020

Chief of Pfizer says political talk around COVID-19 vaccine is 'undercutting public confidence'

The CEO of Pfizer, one of the companies working to develop a vaccine for COVID-19, expressed his disappointment over the politicization of the vaccine's development.

Washington Examiner | October 1, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.5171 seconds.